Top 15 Specialty Pharmacies of 2025: Report

Why It Matters

The dominance of PBM‑owned pharmacies reinforces consolidation trends that shape pricing power and access to high‑cost therapies. Hospital expansion signals a shift toward integrated care models, while independents face mounting pressure to scale or specialize.

Key Takeaways

• PBM-owned pharmacies generate two‑thirds of specialty revenue.
• Accredited specialty sites exceed 1,900, a 3% YoY rise.
• Hospital pharmacy locations grew to 553, now 28% of sites.
• Total specialty drug dispensing hit $293.4 B, up 9.6%.
• Independents remain most numerous but lose revenue share.

Pulse Analysis

The specialty pharmacy landscape in 2025 is defined by concentration, with PBM‑linked entities such as CVS Specialty, Accredo and Optum commanding the lion’s share of dispensing revenue. This dominance gives PBMs leverage over pricing negotiations and formulary decisions, influencing the overall cost trajectory of high‑priced biologics and gene therapies. Analysts view the sustained market share as both a barrier to entry for new players and a catalyst for further vertical integration across the healthcare supply chain.

Spending on specialty drugs continued its upward climb, reaching $293.4 billion—a 9.6% increase from 2024. The surge reflects the expanding indications for complex therapies and the growing prevalence of chronic conditions that require specialty treatment. Concurrently, health systems accelerated the rollout of accredited specialty pharmacy locations, jumping from 106 sites in 2017 to 553 in 2025. This hospital‑driven growth not only diversifies the distribution network but also aligns medication management more closely with clinical services, potentially improving outcomes and reducing total cost of care.

Independent specialty pharmacies, while still the most numerous category, are seeing their revenue slice shrink as larger, integrated players capture higher-margin contracts. The pressure to achieve scale forces independents to either consolidate, specialize in niche therapeutic areas, or partner with larger networks. Looking ahead, the market is likely to see continued consolidation, with PBM and health‑system pharmacies expanding their footprints, while independents must innovate or align strategically to remain viable in an increasingly competitive environment.